BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
1.480
-0.020 (-1.33%)
At close: Nov 20, 2024, 4:00 PM
1.500
+0.020 (1.36%)
After-hours: Nov 20, 2024, 7:50 PM EST
BioAtla Employees
BioAtla had 65 employees as of December 31, 2023. The number of employees decreased by 1 or -1.52% compared to the previous year.
Employees
65
Change (1Y)
-1
Growth (1Y)
-1.52%
Revenue / Employee
$169,231
Profits / Employee
-$1,258,723
Market Cap
71.55M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 65 | -1 | -1.52% |
Dec 31, 2022 | 66 | 10 | 17.86% |
Dec 31, 2021 | 56 | 20 | 55.56% |
Dec 31, 2020 | 36 | - | - |
Related Stocks
Company Name | Employees |
---|---|
P3 Health Partners | 400 |
OptimizeRx | 136 |
Armata Pharmaceuticals | 66 |
Aerovate Therapeutics | 51 |
ESSA Pharma | 50 |
Werewolf Therapeutics | 47 |
Quince Therapeutics | 32 |
Oncolytics Biotech | 29 |
BCAB News
- 12 days ago - BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy - Seeking Alpha
- 6 weeks ago - BioAtla: Numerous Catalysts Coming In Q4 - Seeking Alpha
- 6 weeks ago - BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 7 weeks ago - BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress - GlobeNewsWire
- 2 months ago - BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - GlobeNewsWire
- 3 months ago - BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day - GlobeNewsWire